XR Securities’s Iovance Biotherapeutics IOVA Stock Holding History

XR Securities’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,963	Closed	-$230K	–	517
2020 Q4	$230K	Buy	+4,963	New	+$197K	0.02%	187

Other funds holding IOVA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

XR Securities's IOVA Position: Q1 2021 in Review

XR Securities sold out of Iovance Biotherapeutics (IOVA) in Q1 2021, closing a stake of 4,963 shares — an estimated $230K sold.

XR Securities first reported a position in IOVA in Q4 2020 and held it in 1 quarter. The position peaked at $230K in Q4 2020. 251 funds tracked by Wall St. Rank hold IOVA as of Q1 2021.

XR Securities reported no remaining Iovance Biotherapeutics position as of Q1 2021 after selling out during the quarter.
XR Securities sold 4,963 Iovance Biotherapeutics shares in Q1 2021, an estimated $230K.
XR Securities first reported a position in Iovance Biotherapeutics in Q4 2020 and held it in 1 quarter.
XR Securities's Iovance Biotherapeutics position peaked at $230K in Q4 2020.
251 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2021.

Based on XR Securities's 13F filing for Q1 2021, filed 29 Apr 2021.